Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.

Molecular oncology - 1 Apr 2026

Aanestad Kristin Løge, Austdal Marie, Nordgård Oddmund, Mellgren Gunnar, Oltedal Satu, Austbø Marie L, Vignes Ylva H, Helland Thomas, Jonsdottir Kristin, Lende Tone H, Janssen Emilius A M, Gilje Bjørnar, Tjensvoll Kjersti

Abstract excerpt

Breast cancer is known for late recurrences, yet current follow-up lacks radiological or blood-based monitoring for systemic relapse. This study evaluated circulating tumor DNA (ctDNA) monitoring for early detection of systemic relapse after curative treatment. In this case-control study of 70 patients with operable breast cancer (35 with relapse and 35 without relapse), blood samples were collected every...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Case-Control Studies

Share to Circulating Tumor DNA

Share to Early Detection of Cancer

Share to Neoplasm Recurrence, Local

Source

Open in PubMed Open full text

Identifiers

PMID: 41307327
DOI: 10.1002/1878-0261.70170
PMCID: PMC13060637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer.PMID 41307327Read ↗

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Semantic proximity Read ↗

Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity Read ↗

Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapySemantic proximity Read ↗

Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors.Semantic proximity Read ↗

Circulating tumor DNA as a predictive marker of recurrence for patients with stage II-III breast cancer treated with neoadjuvant therapySemantic proximity Read ↗

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assaySemantic proximity Read ↗

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survivalSemantic proximity Read ↗

Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.Semantic proximity Read ↗

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity Read ↗

Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.Semantic proximity Read ↗

Breast cancer: Tracking ctDNA to evaluate relapse risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.